Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
出版年份 2016 全文链接
标题
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
作者
关键词
-
出版物
RHEUMATOLOGY
Volume -, Issue -, Pages kew370
出版商
Oxford University Press (OUP)
发表日期
2016-12-25
DOI
10.1093/rheumatology/kew370
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The multifactorial role of neutrophils in rheumatoid arthritis
- (2014) Helen L. Wright et al. Nature Reviews Rheumatology
- Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients
- (2012) Damini Jawaheer et al. ARTHRITIS CARE & RESEARCH
- The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
- (2011) J. R. Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- IL-6 plays an essential role in neutrophilia under inflammation
- (2011) Misato Hashizume et al. CYTOKINE
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
- (2010) J. B. Galloway et al. RHEUMATOLOGY
- Neutropenia in patients receiving anti-tumor necrosis factor therapy
- (2010) Richard Hastings et al. ARTHRITIS CARE & RESEARCH
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started